Search - tctmd.com

Displaying 1 - 20 of 28

Sort: Relevancy | Date

News Daily News

Current or Prior Cancers Affect PCI Outcomes Differently, Large Analysis Shows

L.A. McKeown

December 04, 2018

News Daily News

US and European DAPT Guidelines More Alike Than Different, Say Experts

Yael L. Maxwell

December 03, 2018

News Daily News

Debate Over BMS vs DES in High-Bleeding-Risk Scenarios Gets Fresh Fuel in Meta-analysis

Yael L. Maxwell

November 05, 2018

Presentation TCT 2018

Case #5: A Case in Which I Used OCT to Reduce DAPT Duration

Presenter: David Erlinge, Gary S. Mintz, Martin W. Bergmann, Marc D. Feldman, Margaret B. McEntegart, Yasunori Ueda, Carlo Zivelonghi, Robert-Jan van Geuns

September 24, 2018

Presentation TCT 2018

COMPASS Trial Revisited: Weighing Rivaroxaban Secondary Prevention vs DAPT After PCI

Presenter: Deepak L. Bhatt, Tullio Palmerini, Michael Maeng

September 23, 2018

Presentation TCT 2018

Ultra-Short DAPT (1 3 Months): For Which Patients and Stents Do We Have Evidence?

Presenter: Deepak L. Bhatt, Tullio Palmerini, Philip M. Urban

September 23, 2018

Presentation TCT 2018

Patient Selection for Prolonged DAPT: Risk Scores or Wise Clinical Judgement?

Presenter: Deepak L. Bhatt, Tullio Palmerini, Usman Baber

September 23, 2018

Presentation TCT 2018

Who Is the High Bleeding Risk Patient, and How Should DAPT Duration Be Weighed Against Ischemic Risk?

Presenter: Deepak L. Bhatt, Tullio Palmerini, Roxana Mehran

September 23, 2018

Polymer-Free BioFreedom Stent as Safe as Orsiro, but Not as Effective

News Conference News TCT 2018

CORRECTION: Polymer-Free BioFreedom Stent Faces Off Against Orsiro

Michael O'Riordan

September 22, 2018

Presentation TCT 2018

Case Conclusion

Presenter: Philip M. Urban, Robert W. Yeh, Michael A. Kutcher, Michelle O'Donoghue, Elmir Omerovic, Manel Sabate, Daniel I. Simon, Giuseppe Tarantini

September 22, 2018

Presentation TCT 2018

DAPT Duration Case Presentation #2: PCI in Stable CAD With LMCAD and MVD, Case Introduction

Presenter: Philip M. Urban, Robert W. Yeh, Michael A. Kutcher, Michelle O'Donoghue, Elmir Omerovic, Manel Sabate, Daniel I. Simon, Giuseppe Tarantini

September 22, 2018

Presentation TCT 2018

DAPT Duration Case Presentation #1: NSTEMI in a High Bleeding Risk Patient, Case Introduction

Presenter: Philip M. Urban, Robert W. Yeh, Michael A. Kutcher, Michelle O'Donoghue, Elmir Omerovic, Manel Sabate, Daniel I. Simon, Giuseppe Tarantini

September 22, 2018

Presentation TCT 2018

Stent Selection for 1-3 Month DAPT: Current Evidence, Ongoing Studies

Presenter: Philip M. Urban, Robert W. Yeh, Stephan Windecker

September 22, 2018

Presentation TCT 2018

Algorithmic Pharmacology Recommendations for the PCI Patient With Atrial Fibrillation

Presenter: Philip M. Urban, Robert W. Yeh, C. Michael Gibson

September 22, 2018

Presentation TCT 2018

Latest Thinking on DAPT Duration: Balancing Risk vs Benefit

Presenter: Philip M. Urban, Robert W. Yeh, Tullio Palmerini

September 22, 2018

News Conference News ESC 2018

Atrial Fibrillation, Oral Anticoagulation Linked With Mortality After TAVR: FRANCE-TAVI

Michael O'Riordan

August 25, 2018

News Conference News EuroPCR 2018

DCBs for CAD in Certain Patients With Large Vessel De Novo Disease? DEBUT Says Yes

Caitlin E. Cox

May 25, 2018

News Daily News

Less Bleeding, Similar Outcomes With Dual vs Triple Therapy After PCI in Patients With A-fib

Todd Neale

April 24, 2018

News Daily News

Device Thrombus After LAA Closure Strongly Linked to Stroke in Real-World Registry

Todd Neale

April 03, 2018

News Conference News ACC 2018

Too Soon for 6-Month DAPT, Say SMART-DATE Investigators, Despite Positive Trial

Yael L. Maxwell

March 12, 2018

Advertisement

Current or Prior Cancers Affect PCI Outcomes Differently, Large Analysis Shows

US and European DAPT Guidelines More Alike Than Different, Say Experts

Debate Over BMS vs DES in High-Bleeding-Risk Scenarios Gets Fresh Fuel in Meta-analysis

Case #5: A Case in Which I Used OCT to Reduce DAPT Duration

COMPASS Trial Revisited: Weighing Rivaroxaban Secondary Prevention vs DAPT After PCI

Ultra-Short DAPT (1 3 Months): For Which Patients and Stents Do We Have Evidence?

Patient Selection for Prolonged DAPT: Risk Scores or Wise Clinical Judgement?

Who Is the High Bleeding Risk Patient, and How Should DAPT Duration Be Weighed Against Ischemic Risk?

CORRECTION: Polymer-Free BioFreedom Stent Faces Off Against Orsiro

Case Conclusion

DAPT Duration Case Presentation #2: PCI in Stable CAD With LMCAD and MVD, Case Introduction

DAPT Duration Case Presentation #1: NSTEMI in a High Bleeding Risk Patient, Case Introduction

Stent Selection for 1-3 Month DAPT: Current Evidence, Ongoing Studies

Algorithmic Pharmacology Recommendations for the PCI Patient With Atrial Fibrillation

Latest Thinking on DAPT Duration: Balancing Risk vs Benefit

Atrial Fibrillation, Oral Anticoagulation Linked With Mortality After TAVR: FRANCE-TAVI

DCBs for CAD in Certain Patients With Large Vessel De Novo Disease? DEBUT Says Yes

Less Bleeding, Similar Outcomes With Dual vs Triple Therapy After PCI in Patients With A-fib

Device Thrombus After LAA Closure Strongly Linked to Stroke in Real-World Registry

Too Soon for 6-Month DAPT, Say SMART-DATE Investigators, Despite Positive Trial

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content